ESR1 and breast cancer: Because of the low sensitivity of ER+ BC to chemotherapy (22, 23), it is critical to identify a reliable biomarker to predict chemotherapy response and identify patients who are likely to benefit from neoadjuvant chemotherapy to avoid unnecessary treatment.